About the Authors
- Veera R. Konda
-
* E-mail: veerakonda@kindextherapeutics.com
Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America
- Anuradha Desai
-
Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America
- Gary Darland
-
Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America
- Neile Grayson
-
Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America
- Jeffrey S. Bland
-
Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America
Competing Interests
The authors have declared that there is no duality of interest associated with this manuscript. The authors have the following interests: All authors of the manuscript work or have worked as employees of or consultants for KinDex Therapeutics, LLC, which funded this study, and this article was created during the course of that work. Phase 1 clinical development of KDT501 has been successfully completed and further clinical development studies of this compound are anticipated. There are no declarations concerning marketed products. KinDex holds the following patent relating to material pertinent to this research: US 8, 410, 178 B2. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. All authors also declare no conflict of interest resulting from financial or non-financial competing interests.
Author Contributions
Conceived and designed the experiments: VK AD GD NG JB. Performed the experiments: AD. Analyzed the data: VK GD. Contributed reagents/materials/analysis tools: AD VK GD NG. Wrote the paper: AD VK GD NG JB.